Trial Profile
CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2022
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
- Acronyms CORIMUNO19-ECU
- 23 Apr 2020 Planned End Date changed from 1 Aug 2020 to 31 Dec 2020.
- 23 Apr 2020 Planned primary completion date changed from 1 May 2020 to 30 Sep 2020.
- 23 Apr 2020 Status changed from not yet recruiting to recruiting.